Table 4

Agreement between primary care-derived CKD stage (NCKDA) and secondary care-derived eGFR stage (MINAP)

% agreementKappa statistic (SE)
Overall*57.20.42 (0.012)
CKD stages 3a, 3b, 4–553.20.34 (0.015)
CKD stages 1–2, 3a–5‡82.10.55 (0.021)
Overall,* by time from NCKDA SCr test (primary care) to MINAP SCr test (at AMI secondary care admission)
0–5 months61.00.48 (0.03)
6–11 months56.70.42 (0.02)
12–23 months55.90.40 (0.02)
24–36 months56.80.41 (0.04)
  • *Overall agreement when grouping as (1) Stages 1–2 (eGFR 60–120 mL/min/1.73 m2), (2) Stage 3a (eGFR 45–59 mL/min/1.73 m2), (3) Stage 3b (eGFR 30–44 mL/min/1.73 m2) and (4) Stages 4–5 (eGFR 0–30 mL/min/1.73 m2).

  • †Agreement when restricting to people with CKD stages 3a–5, grouped as (1) Stage 3a (eGFR 45–59 mL/min/1.73 m2), (2) Stage 3b (eGFR 30–44 mL/min/1.73 m2) and (3) Stages 4–5 (eGFR 0–30 mL/min/1.73 m2).

  • ‡Agreement when grouping as (1) Stages 1–2 (eGFR 60–120 mL/min/1.73 m2) and (2) Stages 3a–5 (eGFR 0–59 mL/min/1.73 m2).

  • AMI, acute myocardial infarction; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MINAP, Myocardial Ischaemia National Audit Project; NCKDA, National Chronic Kidney Disease Audit; SCr, serum creatinine; SE, Standard error.